EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

Anne Hamilton; Laura Biganzoli; Robert E. Coleman; L. Mauriac; Philippe Hennebert; Ahmad Awada; M. Nooij; L.V.A.M. Beex; Martine Piccart; Irène Van Hoorebeeck; P.F. Bruning; Dominique de Valeriola

doi:10.1093/annonc/mdf157

Keywords

MedicineMucositisMetastatic breast cancerAnthracyclineNeutropeniaNauseaVomitingToxicityPharmacokineticsBreast cancerRegimenGastroenterologyDoxorubicinInternal medicinePhases of clinical researchCancerPharmacologyChemotherapy

Affiliated Institutions

Related Publications

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien , Nely Wigler , Moshe Inbar +11 more

2004 Annals of Oncology 1672 citations

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Anthony W. Tolcher , Steven Sugarman , Karen A. Gelmon +7 more

PURPOSE: BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules. The antibody is direc...

1999 Journal of Clinical Oncology 266 citations

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Alberto Gabizón

Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique ...

2001 Cancer Investigation 561 citations

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon , Brian Leyland‐Jones , Steven Shak +9 more

Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

2001 New England Journal of Medicine 11312 citations

Publication Info

Year: 2002
Type: article
Volume: 13
Issue: 6
Pages: 910-918
Citations: 104
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

104

OpenAlex

Cite This

APA Style

                            
                                
                                    Anne Hamilton, 
                                
                                    Laura Biganzoli, 
                                
                                    Robert E. Coleman
                                
                                et al.
                            
                            (2002). 
                            EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. 
                            Annals of Oncology
                            , 13
                            (6)
                            , 910-918.
                            https://doi.org/10.1093/annonc/mdf157
                        

Identifiers

DOI: 10.1093/annonc/mdf157